Glaukos Corporation

NYSE:GKOS Stock Report

Market Cap: US$7.9b

Glaukos Management

Management criteria checks 3/4

Glaukos' CEO is Tom Burns, appointed in Apr 2002, has a tenure of 22.58 years. total yearly compensation is $8.65M, comprised of 8.8% salary and 91.2% bonuses, including company stock and options. directly owns 2.68% of the company’s shares, worth $212.51M. The average tenure of the management team and the board of directors is 4.1 years and 10.3 years respectively.

Key information

Tom Burns

Chief executive officer

US$8.7m

Total compensation

CEO salary percentage8.8%
CEO tenure22.6yrs
CEO ownership2.7%
Management average tenure4.1yrs
Board average tenure10.3yrs

Recent management updates

Here's Why Glaukos Corporation's (NYSE:GKOS) CEO Compensation Is The Least Of Shareholders' Concerns

May 24
Here's Why Glaukos Corporation's (NYSE:GKOS) CEO Compensation Is The Least Of Shareholders' Concerns

Recent updates

Is Glaukos (NYSE:GKOS) Using Debt In A Risky Way?

Sep 18
Is Glaukos (NYSE:GKOS) Using Debt In A Risky Way?

Glaukos Corporation: Ripe For Some Consolidation

Sep 11

Glaukos Corporation's (NYSE:GKOS) Intrinsic Value Is Potentially 81% Above Its Share Price

Aug 28
Glaukos Corporation's (NYSE:GKOS) Intrinsic Value Is Potentially 81% Above Its Share Price

Glaukos Corporation (NYSE:GKOS) Just Reported And Analysts Have Been Lifting Their Price Targets

Aug 07
Glaukos Corporation (NYSE:GKOS) Just Reported And Analysts Have Been Lifting Their Price Targets

Glaukos Corporation's (NYSE:GKOS) Popularity With Investors Is Clear

Jul 18
Glaukos Corporation's (NYSE:GKOS) Popularity With Investors Is Clear

Glaukos (NYSE:GKOS) Is Carrying A Fair Bit Of Debt

Jun 11
Glaukos (NYSE:GKOS) Is Carrying A Fair Bit Of Debt

Glaukos Stock: Still Unproven Whether A New Bull Market Has Begun

May 30

Here's Why Glaukos Corporation's (NYSE:GKOS) CEO Compensation Is The Least Of Shareholders' Concerns

May 24
Here's Why Glaukos Corporation's (NYSE:GKOS) CEO Compensation Is The Least Of Shareholders' Concerns

Why Glaukos Corporation (NYSE:GKOS) Could Be Worth Watching

Apr 22
Why Glaukos Corporation (NYSE:GKOS) Could Be Worth Watching

Glaukos Corporation (NYSE:GKOS) Not Lagging Industry On Growth Or Pricing

Apr 04
Glaukos Corporation (NYSE:GKOS) Not Lagging Industry On Growth Or Pricing

Glaukos Corporation's (NYSE:GKOS) Intrinsic Value Is Potentially 69% Above Its Share Price

Feb 21
Glaukos Corporation's (NYSE:GKOS) Intrinsic Value Is Potentially 69% Above Its Share Price

Is Glaukos (NYSE:GKOS) A Risky Investment?

Jan 21
Is Glaukos (NYSE:GKOS) A Risky Investment?

Glaukos: Remains A Hold Due To High Valuation And Negative Profitability

Jan 09

Glaukos Corporation's (NYSE:GKOS) 27% Jump Shows Its Popularity With Investors

Dec 20
Glaukos Corporation's (NYSE:GKOS) 27% Jump Shows Its Popularity With Investors

Why Glaukos Corporation (NYSE:GKOS) Could Be Worth Watching

Nov 03
Why Glaukos Corporation (NYSE:GKOS) Could Be Worth Watching

Health Check: How Prudently Does Glaukos (NYSE:GKOS) Use Debt?

Oct 05
Health Check: How Prudently Does Glaukos (NYSE:GKOS) Use Debt?

Glaukos: Continued Growth Rates, Regulatory Tailwinds, And Support

Sep 01

Is Glaukos (NYSE:GKOS) Using Debt Sensibly?

Jun 28
Is Glaukos (NYSE:GKOS) Using Debt Sensibly?

Glaukos: Revising To Buy On These 3 Catalytic Factors

Jun 16

Risks To Shareholder Returns Are Elevated At These Prices For Glaukos Corporation (NYSE:GKOS)

Apr 19
Risks To Shareholder Returns Are Elevated At These Prices For Glaukos Corporation (NYSE:GKOS)

Health Check: How Prudently Does Glaukos (NYSE:GKOS) Use Debt?

Feb 19
Health Check: How Prudently Does Glaukos (NYSE:GKOS) Use Debt?

Glaukos: Trial Momentum Building, Profitability Differentials Yet To Pull Through

Feb 14

Glaukos sees positive data from mid-stage trial of dry eye treatment

Jan 10

Glaukos: Show Me The Money

Nov 10

Does Glaukos (NYSE:GKOS) Have A Healthy Balance Sheet?

Oct 16
Does Glaukos (NYSE:GKOS) Have A Healthy Balance Sheet?

Glaukos pays $10M upfront to license iVeena's eye disorder therapy IVMED-80

Aug 24

Glaukos: Gross Margins Compressing Despite FY22 Guidance Revision

Aug 04

CEO Compensation Analysis

How has Tom Burns's remuneration changed compared to Glaukos's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$150m

Jun 30 2024n/an/a

-US$159m

Mar 31 2024n/an/a

-US$141m

Dec 31 2023US$9mUS$765k

-US$135m

Sep 30 2023n/an/a

-US$129m

Jun 30 2023n/an/a

-US$126m

Mar 31 2023n/an/a

-US$139m

Dec 31 2022US$6mUS$730k

-US$99m

Sep 30 2022n/an/a

-US$90m

Jun 30 2022n/an/a

-US$56m

Mar 31 2022n/an/a

-US$28m

Dec 31 2021US$7mUS$702k

-US$50m

Sep 30 2021n/an/a

-US$38m

Jun 30 2021n/an/a

-US$60m

Mar 31 2021n/an/a

-US$83m

Dec 31 2020US$6mUS$608k

-US$120m

Sep 30 2020n/an/a

-US$73m

Jun 30 2020n/an/a

-US$71m

Mar 31 2020n/an/a

-US$37m

Dec 31 2019US$6mUS$644k

US$15m

Sep 30 2019n/an/a

-US$19m

Jun 30 2019n/an/a

-US$12m

Mar 31 2019n/an/a

-US$12m

Dec 31 2018US$5mUS$625k

-US$13m

Sep 30 2018n/an/a

-US$14m

Jun 30 2018n/an/a

-US$6m

Mar 31 2018n/an/a

-US$4m

Dec 31 2017US$5mUS$600k

-US$92k

Compensation vs Market: Tom's total compensation ($USD8.65M) is about average for companies of similar size in the US market ($USD7.78M).

Compensation vs Earnings: Tom's compensation has increased whilst the company is unprofitable.

CEO

Tom Burns (63 yo)

22.6yrs

Tenure

US$8,654,684

Compensation

Mr. Thomas William Burns, also known as Tom, has been the Chief Executive Officer at Glaukos Corporation since April 1, 2022 and serves as its Chairman of the Board since December 31, 2021. He had Presiden...

Leadership Team

NamePositionTenureCompensationOwnership
Thomas Burns
Chairman & CEO22.6yrsUS$8.65m2.68%
$ 212.5m
Joseph Gilliam
President & COO2.6yrsUS$4.18m0.047%
$ 3.7m
Alex Thurman
Senior VP & CFO2.6yrsUS$2.36m0.052%
$ 4.1m
Tomas Navratil
Chief Development Officer4.1yrsUS$2.57m0.048%
$ 3.8m
Mory Gharib
Co-Founderno datano datano data
Christopher Lewis
Vice President of Investor Relations & Corporate Affairsno datano datano data
Robert Davis
Senior VPno datano datano data
Diana Scherer
VP of Compliance & Deputy General Counselno datano datano data
Michele Allegretto
Senior Vice President of Human Resources9.5yrsno datano data
Chris Calcaterra
Executive Vice President of Global Commercial Operations2.6yrsUS$198.66kno data
L. Katz
Chief Medical Officerno datano datano data
Jane Rady
Senior Vice President of Corporate Strategy & Business Development6.6yrsno datano data

4.1yrs

Average Tenure

58yo

Average Age

Experienced Management: GKOS's management team is considered experienced (4.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Thomas Burns
Chairman & CEO22.7yrsUS$8.65m2.68%
$ 212.5m
Gilbert Kliman
Independent Director4.7yrsUS$259.00k0.054%
$ 4.3m
Richard Lindstrom
Member of Scientific Advisory Boardno datano datano data
Aimee Weisner
Independent Director10.3yrsUS$259.00k0.075%
$ 5.9m
Mark Foley
Lead Independent Director10.3yrsUS$319.38k0.054%
$ 4.3m
David Hoffmeister
Independent Director10.3yrsUS$262.13k0.066%
$ 5.2m
Iqbal Ahmed
Member of Scientific Advisory Boardno datano datano data
Thomas Samuelson
Member of Scientific Advisory Boardno datano datano data
Marc Stapley
Independent Director10.3yrsUS$273.39k0.050%
$ 4.0m
Kuldev Singh
Member of Scientific Advisory Boardno datano datano data
Richard Lewis
Member of Scientific Advisory Boardno datano datano data
John Berdahl
Member of Scientific Advisory Boardno datano datano data

10.3yrs

Average Tenure

61yo

Average Age

Experienced Board: GKOS's board of directors are seasoned and experienced ( 10.3 years average tenure).